FibroGen Reports UK Court Ruling
FibroGen, Inc (FGEN)
Last fibrogen, inc earnings: 3/2 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
phx.corporate-ir.net/phoenix.zhtml?c=253783&p=irol-irhome
Company Research
Source: GlobeNewswire
SAN FRANCISCO, April 20, 2020 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that the United Kingdom’s High Court of Justice has held certain patents1 relating to methods of using hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHIs) to be invalid. This decision does not affect the validity of these patents across the rest of Europe. While FibroGen is disappointed with the court’s decision, this UK ruling does not affect development or commercialization timelines for roxadustat, FibroGen’s HIF-PHI for treatment of anemia in chronic kidney disease, including in the UK or elsewhere in Europe. Roxadustat is a first-in-class small molecule HIF-PH inhibitor approved in China for the treatment of anemia in chronic kidney disease (CKD) patients on dialysis and not on dialysis, and approved in Japan for the treatment of anemia in CKD patients on dialysis, with a supplemental NDA for the non-dialysis indication submitted this past January. The U.S. NDA for ro
Show less
Read more
Impact Snapshot
Event Time:
FGEN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
FGEN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
FGEN alerts
High impacting FibroGen, Inc news events
Weekly update
A roundup of the hottest topics
FGEN
News
- FibroGen to Present at the Oppenheimer Movers in Rare Disease Summit [Yahoo! Finance]Yahoo! Finance
- FibroGen to Present at the Oppenheimer Movers in Rare Disease SummitGlobeNewswire
- FibroGen Inc (FGEN) Q3 2025 Earnings Call Highlights: Strategic Moves Bolster Financial ... [Yahoo! Finance]Yahoo! Finance
- FibroGen, Inc. (FGEN) Q3 2025 Earnings Call Transcript [Seeking Alpha]Seeking Alpha
- FibroGen Reports Third Quarter 2025 Financial Results and Provides Business Update [Yahoo! Finance]Yahoo! Finance
FGEN
Earnings
- 11/10/25 - Beat
FGEN
Analyst Actions
- 9/24/25 - HC Wainwright
FGEN
Sec Filings
- 11/17/25 - Form 4
- 11/14/25 - Form SCHEDULE
- 11/10/25 - Form 10-Q
- FGEN's page on the SEC website